Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02872987 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

Study acronym: GMALLregistry
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Trial sites reduced: 152 → 147 locationsv7
  2. Notable Primary completion date: Dec 2025 to Dec 2030 Study sites: 51 to 152 · Completion date: Dec 2030 to Dec 2035v6 Show 2 more changesShow less
    • Study sites: 51 to 152
    • Completion date: Dec 2030 to Dec 2035
  3. Minor 2 versions Re-verified since Aug 12, 2019, no change to tracked fieldsv4-v5
  4. Notable Lead sponsor: Johann Wolfgang Goethe University Hospital to Goethe University Completion date: Dec 2030 · Study sites revised (51)v3 Show 2 more changesShow less
    • Completion date: Dec 2030
    • Study sites revised (51)

    See this version in full on ClinicalTrials.gov ↗

  5. Minor Study sites: 1 to 51v2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Trial Details
NCT Number NCT02872987
Lead Sponsor Goethe University
Conditions Acute Lymphoblastic Leukemia, Leukemia, Non-Hodgkin's Lymphoma
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov